Open Access

SGLT2 inhibitors in practice (part 1): what is the state of heart failure treatment in 2022?

Event: ESC Congress 2022
Topic: Chronic Heart Failure, Other
Session type: Satellite Symposium
Sponsored by Boehringer Ingelheim & Eli Lilly
Date: 26 August 2022
Time: 15:30 - 16:15

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

Welcome and introduction.

Speaker: Professor J. Butler (Jackson, US)
Thumbnail

What is the evidence for SGLT2 inhibitors in HF?

Speaker: Professor I. Pina (Philadelphia, US)
Thumbnail

SGLT2 inhibitors for HF treatments in 2022 - What do the guidelines tell us?

Speaker: Professor G. Rosano (London, GB)
Thumbnail

Panel discussion.

Speaker: Professor S. Anker (Berlin, DE)
Thumbnail

4 speakers from this session

Professor Javed Butler

The University of Mississippi Medical Center, Jackson (United States of America)
71 presentations
5 followers

Professor Ileana Pina

Thomas Jefferson University, Philadelphia (United States of America)
22 presentations
2 followers

Professor Giuseppe M C Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)
64 presentations
13 followers

Professor Stefan Anker

Charite Universitatsmedizin Berlin, Berlin (Germany)
116 presentations
4 followers

This platform is supported by

logo Novo Nordisk